independent risk factor for cardiovascular disease. The atherosclerosis process in diabetes is indistinguishable from that of the nondiabetic population, but it begins earlier and is often more extensive and more severe.
Introduction
Diabetes mellitus (DM) is a powerful and independent risk factor for cardiovascular disease which remains to be the major cause of death in type 2 diabetic patients [1, 2] . Low grade inflammation and activation of the immune system play a role in the common pathogenesis of both insulin resistance and endothelial dysfunction and subsequently the development of type 2 diabetes and atherosclerosis [2] [3] [4] .
Subclinical vascular disease in type 2 diabetic patients was proved to be assessed by carotid intima media thickness (CIMT) [5] [6] [7] and the presence of plaques (calcified or not) [8] specially in patients with normal renal function by many researches. The dyslipidemic lipid profile (increased LDL and total cholesterol) usually associated with type 2 diabetes and adds more impact to the process of atherosclerosis process development in these patients [9] [10] [11] .
AIF-1 (ionized calcium-binding adaptor molecule-1 (Iba1) is a 17 kDa conserved structural cytoplasmic, calcium-binding, inflammation-responsive scaffold protein [12, 13] . It is one of the EF hand proteins' family [14, 15] .
AIF-1 was originally identified in rat cardiac allografts with chronic rejection. In humans, AIF-1 is involved in many pathological processes where it has been found to be expressed by activated T cells, vascular endothelial cells and blood vessel smooth muscle cells after a balloon injury ie: vascular trauma inducible cytokine [16, 17] . Thus AIF-1 may play a role in endothelial dysfunction, macrophages and VSMCs activation, migration, reorganization and tissue remodelling as a response to endothelial damage [3, 16, 18] .
The in vivo expression of AIF-1 in human VSMCs in atherosclerotic plaques supported the in vitro studies that have shown the role of AIF-1 in atherosclerotic plaque formation through promotion of chemotaxis, cell attachment, spreading and migration of macrophages and VSMCs [19] .
This work aimed was to study serum AIF-1 in type 2 diabetic patients.
Materials and methods
One hundred subjects were included in the study after approval of the ethical committee of Medical Research Institute and informed consents was taken. The included subjects were divided into two groups; Forty apparently healthy volunteers as a control group (group 1), sixty type 2 diabetic patients (group 2). Subjects with obesity, urinary tract infections UTI and renal impairment or increased urinary proteins were excluded. The source of finance was supplied by authors.
To all studied subjects; thorough history taking was done including history of cardiovascular diseases, smoking habits, drinking habits, medications such as anti-diabetic, anti-hypertensive and anti-hyperlipemic drugs. Complete physical examination with special stress on BMI calculation, cardiovascular examination and measuring the carotid intima media thickness (CIMT) and presence of plaques (calcified or not) using a b mode ultrasound.
The following laboratory investigations were done to all participating subjects: quantitation of urinary albumin, urinary proteins, creatinine, calculation of urinary albumin and protein to creatinine ratio, estimation of serum fasting and postprandial glucose, urea, creatinine, calculation of estimated glomerular filtration rate (eGFR) [20] , urine cultures and determination of hemoglobin A 1c [21] . In addition to estimation of serum lipid profile (total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglycerides with calculation of low density lipoprotein cholesterol (LDL-C). Also, serum C-reactive protein (CRP) [22] was estimated and serum AIF-1 by ELISA technique (Biocompare, South San Francisco, USA, catalog no. SEC288Hu) [23] .
Data analysis was performed by using SPSS for Windows, version 20 (Statistical Package of social sciences, Chicago, USA) [24] . Normality of the quantitative variables was determined with the use of the Kolmogrov--Smirnov test. Where normally distributed data were presented as mean ± standard deviation and unpaired Student's t-test was used to compare a variable across two subgroups in addition to Pearson's correlation test was used to investigate the relationship between different quantitative variables. The non-normal distributed data were presented as median (minimum-maximum). Non parametric Mann-Whitney test was used to compare the variables across two groups. Stepwise multiple regression analysis was conducted to test the variables contributing in the AIF-1 marker.
Results
Blood pressure, CIMT and presence of plaques and calcification in type 2 diabetic patients was significantly increased comparing to controls (p = 0.004, p = 0.000, p = 0.013) respectively (Table 1) .
Glycemic control measures showed significant increase in fasting, post prandial blood glucose and HbA 1c in type 2 diabetic patients than controls (p = 0.000, p = 0.000, p = 0.000) respectively ( Table 2) . Lipid profile and CRP levels showed significant increase in cholesterol, triglycerides, LDL and CRP in type 2 diabetic patients than control (p = 0.003, p = 0.000, p = 0.000, p = 0.000) respectively ( Table 2) .
Renal functions tests showed only a significant increase in albumin creatinine ratio in the type 2 diabetic patients than controls (p = 0.04) ( Table 2) .
AIF-1 showed significant increase in type 2 diabetic patients than control group (p = 0.000) (Table 2, Figure 1 ).
Pearson's correlation test showed positive significant correlations only between AIF-1 and creatinine level in addition to CIMT (r = 0.3380, r = 0.468) (p = 0.008, p = 0.000) respectively in type 2 diabetic patients ( Table 3) .
Multiple regression analysis showed the overall model was statistically significant (F = 3.309, p = 0.001). Where, CIMT was significantly positive contributing to the outcome variable (AIF-1) (p < 0.05), while other predictors were not significantly contributing to the outcome (p > 0.05) ( Table 4 ).
Discussion
Diabetes when accompanied by other major cardiovascular risk factors, such as hypertension, dyslipidemia, and smoking, show marked increase in the incidence of atherosclerosis. The atherosclerosis process begins earlier and more aggressive in diabetes and indistinguishable from nondiabetic population [2] . The atherogenic lipid profile characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol are major modifiable risk factors contributing to progressive cardiovascular risk generally in addition to both type 2 diabetes and metabolic syndrome [25, 26] .
Atherosclerosis is known to be an inflammatory disease as an overall process where inflammatory cells (pro-inflammatory cytokines secreting cells) such as neutrophils, lymphocytes and monocytes participate in the overall process of atheroscelerosis [27] .
AIF-1 plays a role in endothelial cell, macrophage, T-lymphocyte, and VSMC activation, proliferation and migration which are known to play a role in inflammation [3, 16, 18] .
It has been shown that serum AIF-1 was increased in patients with diabetic nephropathy [23] , also it is considered as a human adipokine produced mainly by macrophages within the white adipose tissue in obese patients and might participate in the regulation of adi-pose tissue inflammation and, in turn, insulin resistance [28] . In the present study, all the studied groups were of normal e GFR and BMI.
The level of AIF-1 was significantly higher in type 2 diabetic groups when compared to the control group (p = 0.000) (Figure 1 ). The statistical correlation in our study revealed that there was a significant positive correlation between CIMT and AIF-1 (r = 0.468, p = 0.000) in type 2 diabetic patients group, denoting the possible role of elevated serum AIF-1 level in atherosclerotic process. In addition the significant increase in the presence of plaques and calcification in the patients than controls (p = 0.013) has been seen. Although there is significant increase in dyslipidemic profile of type 2 diabetic patients than controls (cholesterol, triglycerides and LDL (p = 0.003, p = 0.000, p = 0.000) which add to the process of atherosclerosis development in these patients, there were no significant correlations between dyslipidemia and AIF-1 level in these patients thus a study on larger scale of type 2 diabetic patients is needed.
In multiple linear regression analysis, the overall model is statistically significant (F = 3.309, p = 0.001) and it is found that increased CIMT is significantly contributing to elevated serum AIF-1 level in type 2 diabetic patients (p < 0.05). Thus, elevated serum AIF-1 level in type 2 diabetic patients in addition to its positive significant correlation with CIMT add to the possible role of AIF1 in contribution to the process of atherosclerotic changes in type 2 diabetic patients. This was consistent with Berglund et al., 2012 [29] who stated that expression of AIF-1 mRNA in human carotid plaques associates with less extracellular matrix and a more pro-inflammatory plaque and plasma profile, features that may predispose to plaque rupture. Zhao et al, 2013 [14] reported that AIF-1 is expressed by activated lipid-rich macrophages and VSMCs during the progression of atherosclerosis. In this regard, AIF-1 may be involved in the early stage of atherosclerosis and CAD. Kelemen et al, in 2005 [30] stated that increased AIF-1 expressed in activated T lymphocytes enhance activation of adjacent arterial vascular smooth muscle cells (VSMCs) and development of atherosclerosis. Expression of AIF-1 seems to be involved in vascular smooth muscle cells and macrophages migration, chemotaxis, proliferation and tissue remodeling as a response to endothelial damage which suggest a positive role of AIF-1 in the atherosclerotic plaque formation. These in vitro studies were supported by immunohistochemical analysis which has shown in vivo protein expression of AIF-1 in human smooth muscle cells in atherosclerotic plaques [19] .
In the present work, by drawing receiver operating characteristic (ROC) curve of serum AIF-1 at a cutoff value of 120 pg/mL in the studied group (Figure 2) , the area under the curve (AUC) for AIF-1 was 0.843, p ≤ 0.0001. The sensitivity, specificity, positive predictive value, negative predictive value and overall accuracy of AIF-1 for detection of atherosclerosis were 98.33%, 70%, 91%, 93% and 91% respectively. Thus, the present study supported that AIF-1 can be a helpful marker for early detection of atherosclerosis and prediction of cardiovascular complications in type 2 diabetic patients.
Conclusion
In conclusion, AIF-1 was significantly higher in the type 2 diabetic patient group (group 2) when compared to the control group (group 1). In the group of type 2 diabetic patients AIF-1 showed positive correlation with CIMT denoting the possible relation between increased AIF-1 levels and subsequent vascular damage and the process of atherosclerosis in type 2 diabetes.
Recommendations: further work is needed on a larger number of type 2 diabetic patients with higher focus on the presence of vascular calcification and atherosclerosis.
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